{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:50:14Z","timestamp":1771048214437,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jns.2017.11.028","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T08:02:34Z","timestamp":1511424154000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis"],"prefix":"10.1016","volume":"385","author":[{"given":"Sarah A.","family":"Morrow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Rosehart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp","family":"Sener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blayne","family":"Welk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.11.028_bb0005","first-page":"CD004193","article-title":"Anticholinergics for urinary symptoms in multiple sclerosis","volume":"1","author":"Nicholas","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2017.11.028_bb0010","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jns.2017.11.028_bb0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2017.11.028_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1479-8301.2010.00310.x","article-title":"Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease","volume":"10","author":"Konishi","year":"2010","journal-title":"Psychogeriatrics"},{"issue":"2","key":"10.1016\/j.jns.2017.11.028_bb0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.archger.2008.07.011","article-title":"Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI)","volume":"49","author":"Seo","year":"2009","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"3","key":"10.1016\/j.jns.2017.11.028_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000325171","article-title":"Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study","volume":"31","author":"Sittironnarit","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"7539","key":"10.1016\/j.jns.2017.11.028_bb0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jns.2017.11.028_bb0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gps.2157","article-title":"Use of medications with anticholinergic properties and cognitive function in a young-old community sample","volume":"24","author":"Low","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"14","key":"10.1016\/j.jns.2017.11.028_bb0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carriere","year":"2009","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.jns.2017.11.028_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.jns.2017.11.028_bb0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.11.028_bb0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jns.2017.11.028_bb0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00019052-199506000-00010","article-title":"Neuropsychology of multiple sclerosis","volume":"8","author":"Rao","year":"1995","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2017.11.028_bb0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2017.11.028_bb0075","series-title":"Multiple Sclerosis","article-title":"Manual for the brief repeatable battery of neuropsychological tests","author":"Rao","year":"1990"},{"issue":"3","key":"10.1016\/j.jns.2017.11.028_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1076\/clin.16.3.381.13859","article-title":"Minimal neuropsychological assessment of MS patients: a consensus approach","volume":"16","author":"Benedict","year":"2002","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.jns.2017.11.028_bb0085","article-title":"Brief visuospatial memory test-revised: professional manual. Odessa, Fl.: psychological assessment","author":"Benedict","year":"1997","journal-title":"Resources"},{"key":"10.1016\/j.jns.2017.11.028_bb0090","series-title":"California Verbal Learning Test: Adult Version","author":"Delis","year":"2000"},{"key":"10.1016\/j.jns.2017.11.028_bb0095","article-title":"Symbol digit modalities test. Manual. Los Angeles: western","author":"Smith","year":"1982","journal-title":"Psychol. Serv."},{"issue":"4","key":"10.1016\/j.jns.2017.11.028_bb0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"12","author":"Benedict","year":"2006","journal-title":"J. Int. Neuropsychol. Soc."},{"issue":"11","key":"10.1016\/j.jns.2017.11.028_bb0105","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/1352458510378021","article-title":"Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks","volume":"16","author":"Morrow","year":"2010","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.jns.2017.11.028_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jns.2017.11.028_bb0115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.55.7.934","article-title":"Fatigue and declines in cognitive functioning in multiple sclerosis","volume":"55","author":"Krupp","year":"2000","journal-title":"Neurology"},{"issue":"6\u20137","key":"10.1016\/j.jns.2017.11.028_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0024-3205(98)00581-5","article-title":"Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder","volume":"64","author":"Hegde","year":"1999","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.jns.2017.11.028_bb0125","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.jns.2017.11.028_bb0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2017.11.028_bb0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.msard.2012.05.002","article-title":"Cognitive impact of anticholinergic medication in MS: adding insult to injury?","volume":"1","author":"Cruce","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2017.11.028_bb0140","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1017\/S135561770505068X","article-title":"Interpreting patient\/informant discrepancies of reported cognitive symptoms in MS","volume":"11","author":"Carone","year":"2005","journal-title":"J. Int. Neuropsychol. Soc."},{"issue":"1","key":"10.1016\/j.jns.2017.11.028_bb0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/jnp.13.1.70","article-title":"Personality disorder in multiple sclerosis correlates with cognitive impairment","volume":"13","author":"Benedict","year":"2001","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2017.11.028_bb0150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.apmr.2009.09.026","article-title":"Examining the relationship between cognition and driving performance in multiple sclerosis","volume":"91","author":"Schultheis","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"5","key":"10.1016\/j.jns.2017.11.028_bb0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.41.5.692","article-title":"Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.11.028_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2004.12.009","article-title":"Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change","volume":"231","author":"Benedict","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"13","key":"10.1016\/j.jns.2017.11.028_bb0165","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1177\/1352458514533229","article-title":"Characterizing cognitive function during relapse in multiple sclerosis","volume":"20","author":"Benedict","year":"2014","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2017.11.028_bb0170","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00415-011-5975-3","article-title":"Effects of acute relapses on neuropsychological status in multiple sclerosis patients","volume":"258","author":"Morrow","year":"2011","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.11.028_bb0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5213\/inj.1734850.425","article-title":"On the site and mechanism of action of beta3-adrenoceptor agonists in the bladder","volume":"21","author":"Andersson","year":"2017","journal-title":"Int. Neurourol. J."},{"issue":"11","key":"10.1016\/j.jns.2017.11.028_bb0180","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int."},{"issue":"20","key":"10.1016\/j.jns.2017.11.028_bb0185","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1212\/WNL.0000000000000433","article-title":"Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS","volume":"82","author":"Sumowski","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2017.11.028_bb0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1017\/S1355617710000688","article-title":"Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients","volume":"16","author":"Benedict","year":"2010","journal-title":"J. Int. Neuropsychol. Soc."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T17:32:59Z","timestamp":1535218379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17344623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":38,"alternative-id":["S0022510X17344623"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.11.028","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}